These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 2690331)

  • 21. Ranitidine in the treatment of duodenal ulcer disease: relationship between antisecretory effect and ulcer healing rate.
    McIsaac RL; Dixon JS; Mills JG; Wood JR
    Aliment Pharmacol Ther; 1991 Jun; 5(3):227-43. PubMed ID: 1888823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of omeprazole on gastric acid secretion and plasma gastrin in man.
    Olbe L; Cederberg C; Lind T; Olausson M
    Scand J Gastroenterol Suppl; 1989; 166():27-32; discussion 41-2. PubMed ID: 2690329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histamine H2-receptor antagonists in peptic ulcer disease. Efficacy in healing peptic ulcers.
    Deakin M; Williams JG
    Drugs; 1992 Nov; 44(5):709-19. PubMed ID: 1280563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Omeprazole in elderly duodenal ulcer patients: relationship between reduction in gastric acid secretion and fasting plasma gastrin.
    Lind T; Cederberg C; Olausson M; Olbe L
    Eur J Clin Pharmacol; 1991; 40(6):557-60. PubMed ID: 1884735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Omeprazole (20 mg) daily given in the morning or evening: a comparison of effects on gastric acidity, and plasma gastrin and omeprazole concentration.
    Chiverton SG; Howden CW; Burget DW; Hunt RH
    Aliment Pharmacol Ther; 1992 Feb; 6(1):103-11. PubMed ID: 1543812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of melatonin and tryptophan on healing of gastric and duodenal ulcers with Helicobacter pylori infection in humans.
    Celinski K; Konturek PC; Konturek SJ; Slomka M; Cichoz-Lach H; Brzozowski T; Bielanski W
    J Physiol Pharmacol; 2011 Oct; 62(5):521-6. PubMed ID: 22204799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.
    Wilde MI; McTavish D
    Drugs; 1994 Jul; 48(1):91-132. PubMed ID: 7525198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A double-blind randomized study comparing different dose regimens of H2-receptor antagonists on 24-hour gastric secretion in normal subjects and duodenal ulcer patients.
    de Gara CJ; Burget DW; Silletti C; Hunt RH
    Am J Gastroenterol; 1987 Jan; 82(1):36-41. PubMed ID: 3099564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Omeprazole in the therapy of acid-induced diseases].
    Simon B; Dammann HG; Müller P
    Z Gastroenterol; 1987 Aug; 25 Suppl 3():146-51. PubMed ID: 2889299
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Idiopathic gastric acid hypersecretion: treatment implications for refractory acid/peptic disorders.
    Lewis JH
    Aliment Pharmacol Ther; 1991; 5 Suppl 1():15-24. PubMed ID: 1888834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antisecretory effects of three omeprazole regimens for maintenance treatment in duodenal ulcer.
    Savarino V; Mela GS; Zentilin P; Cutela P; Mele MR; Perilli D; Vassallo A; Zambotti A; Mansi C; Celle G
    Dig Dis Sci; 1994 Jul; 39(7):1473-82. PubMed ID: 8026259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Appropriate acid suppression in the treatment of acid-related conditions.
    Howden CW
    Pharmacol Ther; 1994; 63(1):123-34. PubMed ID: 7972343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of omeprazole, a substituted benzimidazole, on 24-h intragastric acidity in patients with peptic ulcer disease.
    Naesdal J; Bodemar G; Walan A
    Scand J Gastroenterol; 1984 Oct; 19(7):916-22. PubMed ID: 6531660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.
    Clissold SP; Campoli-Richards DM
    Drugs; 1986 Jul; 32(1):15-47. PubMed ID: 3527658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simultaneous evaluation of gastric and duodenal ulcers-healing activities of anti-ulcer agents in rats.
    Segami T; Suzuki Y; Ito M
    Biol Pharm Bull; 1996 Jan; 19(1):53-6. PubMed ID: 8820911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Variability in individual response to various doses of omeprazole. Implications for antiulcer therapy.
    Savarino V; Mela GS; Zentilin P; Cutela P; Mele MR; Vigneri S; Celle G
    Dig Dis Sci; 1994 Jan; 39(1):161-8. PubMed ID: 8281852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of refractory peptic ulcer with omeprazole or continued H2 receptor antagonists: a controlled clinical trial.
    Bardhan KD; Naesdal J; Bianchi Porro G; Petrillo M; Lazzaroni M; Hinchliffe RF; Thompson M; Morris P; Daly MJ; Carroll NJ
    Gut; 1991 Apr; 32(4):435-8. PubMed ID: 1673953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. pH, healing rate and symptom relief in acid-related diseases.
    Huang JQ; Hunt RH
    Yale J Biol Med; 1996; 69(2):159-74. PubMed ID: 9112748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 24-hour intragastric acidity and plasma gastrin after omeprazole treatment and after proximal gastric vagotomy in duodenal ulcer patients.
    Lind T; Cederberg C; Olausson M; Olbe L
    Gastroenterology; 1990 Dec; 99(6):1593-8. PubMed ID: 2227275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial.
    Hosking SW; Ling TK; Chung SC; Yung MY; Cheng AF; Sung JJ; Li AK
    Lancet; 1994 Feb; 343(8896):508-10. PubMed ID: 7906759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.